Navigation Links
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Date:5/23/2012

Usage Patterns (millions), 2004-2018 74Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

RocheJohnson & JohnsonPfizerAbbott LaboratoriesBristol-Myers SquibbAmgen

To order this report:Therapy Industry:

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. The Strong Womans Approach to Managing Rheumatoid Arthritis
3. Defect in A20 gene expression causes rheumatoid arthritis
4. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
5. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
6. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
7. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
8. Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)
9. Arthritis drug could help beat melanoma skin cancer
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... state of the global Propanol market with a focus on the Chinese situation. Major ... Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... CHICAGO, July 22 Research presented at the American ... monitoring cardiac transplant patients with the Urine NGAL assay on ... toxicity and adjust doses of cyclosporine drugs to prevent possible ... In a scientific poster presented at AACC today ...
... , , PHILADELPHIA, July 22 ... centralized ECG and eClinical technology, ePRO, and other services to the ... new Vice President of Project Management, Tammy Miller. Ms. Miller will ... In this new role, Ms. Miller will be responsible for the ...
... , , CHICAGO, July 22 Research ... that an assay developed by Abbott for simultaneous detection of both HIV ... in this study compared to HIV antibody-only assays. Earlier detection was ... , "The ability to use a blood test to ...
Cached Biology Technology:Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2ERT Appoints New Vice President of Project Management 2ERT Appoints New Vice President of Project Management 3Abbott HIV Test Demonstrates Earlier Disease Detection 2Abbott HIV Test Demonstrates Earlier Disease Detection 3
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... to protect chickens, cats and humans against deadly flu pandemics, ... the Journal of General Virology . The vaccine protects ... be given to birds while they are still in their ... emergence of bird flu has posed a major challenge to ...
... St. Louis operates one of the largest and fastest ... in the western hemisphere. With the addition of a ... aroid species from Ecuador, the Garden,s permanent collection of ... of six million specimens. A herbarium is essentially ...
... counter-terrorism symposium tomorrow at NJIT from 8:30 a.m. - ... ways to secure schools, health and transportation facilities, protect ... and more. Presenters will include NJ State ... Homeland Security and Preparedness, U.S. Coast Guard and NJ ...
Cached Biology News:Bird flu vaccine protects people and pets 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 3
... These precision 5mm diameter, 7 inch long ... glass for compatibility with ground joints, valves, and ... NMR spectrometers running from 300 to 500MHz. They ... an I.D. of 4.20 + 0.013-0.000mm. These NMR ...
... for nucleic acid electrophoresis in agarose ... Preparation Quantity Equivalency: A final concentration ... stock solution can be made in ... Dye content ~ 75% Special ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
... GenElute Gel Extraction Kit combines silica- binding technology ... column format. DNA fragments of interest are extracted ... the gel. The Gel Solubilization Solution can dissolve ... either TBE or TAE buffer. Extracted DNA fragments ...
Biology Products: